AU751022B2 - Peptides derived from the attachment (G) protein of respiratory syncytial virus - Google Patents

Peptides derived from the attachment (G) protein of respiratory syncytial virus Download PDF

Info

Publication number
AU751022B2
AU751022B2 AU95725/98A AU9572598A AU751022B2 AU 751022 B2 AU751022 B2 AU 751022B2 AU 95725/98 A AU95725/98 A AU 95725/98A AU 9572598 A AU9572598 A AU 9572598A AU 751022 B2 AU751022 B2 AU 751022B2
Authority
AU
Australia
Prior art keywords
amino acid
protein
region
seq
polypeptide
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU95725/98A
Other languages
English (en)
Other versions
AU9572598A (en
Inventor
Gerald E Hancock
Paul W. Tebbey
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Wyeth Holdings LLC
Original Assignee
American Cyanamid Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by American Cyanamid Co filed Critical American Cyanamid Co
Publication of AU9572598A publication Critical patent/AU9572598A/en
Application granted granted Critical
Publication of AU751022B2 publication Critical patent/AU751022B2/en
Assigned to WYETH HOLDINGS CORPORATION reassignment WYETH HOLDINGS CORPORATION Request to Amend Deed and Register Assignors: AMERICAN CYANAMID COMPANY
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18511—Pneumovirus, e.g. human respiratory syncytial virus
    • C12N2760/18522—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Virology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Plant Pathology (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Communicable Diseases (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
AU95725/98A 1997-09-19 1998-09-17 Peptides derived from the attachment (G) protein of respiratory syncytial virus Ceased AU751022B2 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US5968497P 1997-09-19 1997-09-19
US60/059684 1997-09-19
US8486398P 1998-05-08 1998-05-08
US60/084863 1998-05-08
PCT/US1998/019656 WO1999014334A1 (en) 1997-09-19 1998-09-17 Peptides derived from the attachment (g) protein of respiratory syncytial virus

Publications (2)

Publication Number Publication Date
AU9572598A AU9572598A (en) 1999-04-05
AU751022B2 true AU751022B2 (en) 2002-08-08

Family

ID=26739056

Family Applications (1)

Application Number Title Priority Date Filing Date
AU95725/98A Ceased AU751022B2 (en) 1997-09-19 1998-09-17 Peptides derived from the attachment (G) protein of respiratory syncytial virus

Country Status (13)

Country Link
EP (1) EP1015595B1 (enExample)
JP (1) JP2001516583A (enExample)
KR (1) KR100550132B1 (enExample)
CN (1) CN1259422C (enExample)
AT (1) ATE287957T1 (enExample)
AU (1) AU751022B2 (enExample)
BR (1) BR9812240A (enExample)
CA (1) CA2302833C (enExample)
CY (1) CY1105010T1 (enExample)
DE (1) DE69828801T2 (enExample)
ES (1) ES2236946T3 (enExample)
PT (1) PT1015595E (enExample)
WO (1) WO1999014334A1 (enExample)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1334119B2 (en) 2000-10-18 2018-11-28 THE GOVERNMENT OF THE UNITED STATES OF AMERICA, as represented by THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES Compositions and methods for modulating rsv infection and immunity
AUPR520201A0 (en) * 2001-05-23 2001-06-14 Commonwealth Scientific And Industrial Research Organisation Antiviral compounds
NL1019228C1 (nl) 2001-10-25 2003-04-28 Duynstee Holding B V Verbeterd gecombineerd ophang- en verlichtingssysteem voor bijvoorbeeld schilderijen e.d.
US6667327B2 (en) 2002-02-04 2003-12-23 Hoffmann-La Roche Inc. Pyridine amido derivatives
DE10219219A1 (de) 2002-04-29 2003-11-06 Tampoflex Gmbh Druckanlage
WO2004092207A2 (en) * 2003-04-16 2004-10-28 Algonomics N.V. Respiratory syncytial virus (rsv) peptides
US7368537B2 (en) * 2003-07-15 2008-05-06 Id Biomedical Corporation Of Quebec Subunit vaccine against respiratory syncytial virus infection
RU2006117366A (ru) 2003-10-23 2007-12-10 Ф.Хоффманн-Ля Рош Аг (Ch) Производные бензазепина в качестве ингибиторов мао-в
US7666433B2 (en) * 2004-06-30 2010-02-23 Wyeth Holdings Corporation Recombinant RSV strains with altered G protein
EP2181121A4 (en) * 2007-03-21 2012-07-11 Id Biomedical Corp Quebec CHIMÄRE ANTIGENE
US8563002B2 (en) 2007-12-24 2013-10-22 Glaxosmithkline Biologicals, S.A. Recombinant RSV antigens
SG176807A1 (en) 2009-06-24 2012-01-30 Id Biomedical Corp Quebec Vaccine
PL2445526T3 (pl) 2009-06-24 2017-08-31 Glaxosmithkline Biologicals S.A. Rekombinowane antygeny rsv
EP4183412B1 (en) 2009-07-15 2024-08-14 GlaxoSmithKline Biologicals SA Rsv f protein compositions and methods for making same
EP2453903B1 (en) * 2009-07-17 2016-08-17 Industry Academic Cooperation Foundation, Hallym University Immunostimulatory compositions comprising liposome-encapsulated oligonucleotides and epitopes
US8846056B2 (en) 2009-08-04 2014-09-30 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services, Centers For Disease Control Anti-RSV immunogens and methods of immunization
RS56748B1 (sr) 2011-05-13 2018-03-30 Glaxosmithkline Biologicals Sa Pre-fuzioni rsv f antigeni
EP3956351A1 (en) * 2019-04-18 2022-02-23 Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. Biological and synthetic molecules inhibiting respiratory syncytial virus infection

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2944897A (en) * 1996-06-05 1998-01-05 Commonwealth Scientific And Industrial Research Organisation Viral peptides with structural homology to protein g of respiratory syncytial virus

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2726577B1 (fr) * 1994-11-07 1997-01-31 Pf Medicament Procede d'obtention d'un peptide derive du virus respiratoire syncitial, polypeptide et bacterie l'exprimant, et leurs applications a titre de medicament
AUPO026596A0 (en) * 1996-06-05 1996-06-27 Biomolecular Research Institute Limited Viral peptide

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2944897A (en) * 1996-06-05 1998-01-05 Commonwealth Scientific And Industrial Research Organisation Viral peptides with structural homology to protein g of respiratory syncytial virus

Also Published As

Publication number Publication date
CN1259422C (zh) 2006-06-14
DE69828801D1 (de) 2005-03-03
AU9572598A (en) 1999-04-05
KR100550132B1 (ko) 2006-02-08
CA2302833C (en) 2007-05-08
JP2001516583A (ja) 2001-10-02
WO1999014334A1 (en) 1999-03-25
CN1322250A (zh) 2001-11-14
KR20010030620A (ko) 2001-04-16
BR9812240A (pt) 2000-07-18
DE69828801T2 (de) 2005-07-14
CA2302833A1 (en) 1999-03-25
PT1015595E (pt) 2005-05-31
ES2236946T3 (es) 2005-07-16
CY1105010T1 (el) 2010-03-03
EP1015595A1 (en) 2000-07-05
EP1015595B1 (en) 2005-01-26
ATE287957T1 (de) 2005-02-15

Similar Documents

Publication Publication Date Title
US20240408195A1 (en) Epstein-barr virus vaccines
US20250057942A1 (en) Nucleic acid vaccine against the sars-cov-2 coronavirus
EP1015595B1 (en) Peptides derived from the attachment (g) protein of respiratory syncytial virus
KR20140122258A (ko) Rsv 감염의 예방 및 치료를 위한 혼합 항원 및 dna 백신
US12156908B2 (en) Virus like nanoparticle compositions and methods thereof
US20100068226A1 (en) Polynucleotides and Uses Thereof
US20250000968A1 (en) Sars-cov-2 spike fused to a hepatitis b surface antigen
CN103442729A (zh) 疟疾的治疗和预防
US20250186576A1 (en) Sars-cov-2 subunit vaccine
US20230149537A1 (en) Vaccines, adjuvants, and methods of generating an immune response
US6699478B1 (en) Enhanced immune response to attachment (G) protein of Respiratory Syncytial Virus
CA3184406A1 (en) A dna plasmid sars-coronavirus-2/covid-19 vaccine
US20240316183A1 (en) Sars-cov-2 subunit vaccine
US20240197865A1 (en) Compositions and methods for preventing rsv and piv3 infections
CN117003885A (zh) H5n8禽流感广谱性疫苗的开发及其应用
BR112016007868B1 (pt) Nanopartícula, seu uso, proteína de fusão, molécula de ácido nucleico, vacina contra o vírus do epstein-barr e método para a sua produção
BR122024015865A2 (pt) Nanopartícula, seu uso, proteína de fusão, molécula de ácido nucleico, vacina contra o vírus do epstein-barr e método para a sua produção
AU2005260580A1 (en) Recombinant rsv strains with altered g protein

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)
HB Alteration of name in register

Owner name: WYETH HOLDINGS CORPORATION

Free format text: FORMER NAME WAS: AMERICAN CYANAMID COMPANY